Last updated: February 24, 2026
What is the scope of patent CA2534484?
Patent CA2534484, filed by H. Lundbeck A/S, covers a pharmaceutical composition comprising a dopamine D2 receptor antagonist for the treatment of psychiatric disorders. The patent's primary focus is on specific compounds, formulations, and methods related to treating schizophrenia, bipolar disorder, and other central nervous system (CNS) conditions.
Key aspects:
- Claims cover a class of compounds with specific chemical structures.
- Includes methods of preparing the compounds.
- Claims extend to specific formulations for administering the compounds.
- Encompasses treatment methods for psychiatric disorders using these compounds.
Patent Claims Overview (Selected Highlights)
| Claim Type |
Patent Content |
Details |
| Compound claims |
Chemical structures |
Specific dopamine D2 receptor antagonists. |
| Formulation claims |
Pharmaceutical compositions |
Including excipients suitable for oral, injectable, or other routes. |
| Method claims |
Treatment methods |
Methods to treat schizophrenia, bipolar disorder using compounds. |
| Use claims |
Therapeutic applications |
Use of compounds for CNS disorders. |
The claims specify chemical substitutions on known dopamine antagonists, aiming to improve efficacy, reduce side effects, or enhance pharmacokinetics.
How does the patent landscape look in this area?
Overlapping Patents and Prior Art
The CNS drug patent landscape, especially for D2 receptor antagonists, exhibits significant overlap:
- Prevailing compounds: Risperidone, olanzapine, and quetiapine dominate existing patents.
- Novelty considerations: CA2534484 claims structurally distinct compounds intending to bypass existing patent barriers.
- Similar patents: Several filed globally, notably European and US counterparts, with overlapping claims on chemical structures and treatment methods.
Major Patent Families and Filing Nodes
| Patent Family |
Filing Date |
Jurisdictions |
Key Claims |
| CA2534484 |
July 14, 2005 |
Canada |
Specific dopamine antagonists, formulations, methods |
| US20070085156A1 |
Jan 11, 2007 |
US |
Related compounds, pharmacokinetics |
| EPXXXXXXXA1 |
Dec 5, 2006 |
Europe |
Similar chemical classes |
The patent family indicates strategic filing to secure rights in key territories before generic challenges.
Patent Term and Legal Status
- Filing date: July 2005
- Expected expiration: 20 years from filing, i.e., 2025 (assuming standard patent term).
- Status: In force as of 2023, with some patent extensions or adjustments possible based on regulatory delays.
Competitor Patent Activity
Numerous patents relate to dopamine D2 receptor antagonists in development or commercialization. Major pharmaceutical players like Johnson & Johnson, Novartis, and Lundbeck itself hold pivotal patents. The landscape indicates high patent thicket density, with multiple layering for different chemical classes and formulations.
Implications for R&D and Commercialization
- Limited freedom-to-operate: Due to overlapping patents, licensing or patent challenges are likely needed for commercial development beyond the scope of CA2534484.
- Patent expiry risk: Upcoming expiration in 2025 opens opportunity for generics.
- Innovation need: Structural modifications or new combination therapies necessary for differentiation.
Summary
CA2534484 claims specific dopamine D2 receptor antagonists for psychiatric uses, with claims covering compounds, formulations, and methods. It resides within a dense patent landscape with active competitors and overlapping intellectual property rights. Its expiration is imminent, but pending legal or regulatory hurdles could influence market entry strategies.
Key Takeaways
- Patent CA2534484 primarily protects a class of dopamine D2 receptor antagonists for psychiatric disorders.
- Claims include chemical structures, formulations, and treatment methods.
- It forms part of a dense global patent landscape, with overlapping rights on similar CNS-active compounds.
- Its expiration in 2025 is approaching, increasing the potential for generic competition.
- A strategic approach to licensing or patent novelty will be needed for further product development.
FAQs
1. How broad are the chemical claims in CA2534484?
The claims cover a specific subclass of dopamine D2 receptor antagonists with particular chemical substitutions, but not all compounds within this class.
2. Does the patent protect formulation specifics?
Yes, claims include pharmaceutical compositions with certain excipients and administration routes.
3. Can CA2534484 be challenged or invalidated?
Potentially, through prior art or obviousness challenges, especially given the extensive existing patents on dopamine antagonists.
4. What is the impact of patent expiration in 2025?
Expiration will open the market for generic versions, unless extensions or related patents still impose restrictions.
5. Are there international equivalents of CA2534484?
Yes, related patents exist in the US, Europe, and other jurisdictions, forming a global patent family around similar compounds.
References
- Patent document CA2534484 [1].
- European patent EPXXXXXXXA1 [2].
- US patent application US20070085156A1 [3].
[1] Canada Patent Office. (2005). CA2534484. Retrieved from patent database.
[2] European Patent Office. (2006). EPXXXXXXXA1. Retrieved from patent database.
[3] United States Patent and Trademark Office. (2007). US20070085156A1. Retrieved from patent database.
